aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer June 12, 2017 An automated bone scan index (aBSI) at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate cancer (CRPC) with bone metastases, according to data from a phase 3 study presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.Read more.Source: Cancer Therapy Advisor Prostate Cancer News
An automated bone scan index (aBSI) at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate cancer (CRPC) with bone metastases, according to data from a phase 3 study presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.Read more.Source: Cancer Therapy Advisor
